For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody-drug conjugate targeting CLDN6; early data from a phase I trial indicates that it has a favorable safety profile and appears active in this disease.
A Tue, study studied this question.